The Genetics of Alzheimer Disease
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
Family history is the second strongest risk factor for Alzheimer disease (AD) following advanced age.Twin and family studies indicate that genetic factors are estimated to play a role in at least 80% of AD cases.The inheritance of AD exhibits a dichotomous pattern.On one hand, rare mutations in APP, PSEN1, and PSEN2 virtually guarantee early-onset (,60 years) familial AD, which represents 5% of AD.On the other hand, common gene polymorphisms, such as the 14 and 12 variants of the APOE gene, can influence susceptibility for 50% of the common late-onset AD.These four genes account for 30% -50% of the inheritability of AD.Genome-wide association studies have recently led to the identification of 11 additional AD candidate genes.This paper reviews the past, present, and future attempts to elucidate the complex and heterogeneous genetic underpinnings of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“To date, 228 PSEN1 mutations have been identified causing ADAD (49, 303, 304, 440, 566, 580).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [580]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“CLU gene encodes clusterin or APOJ that besides its functions in lipid transport, membrane recycling, cell adhesion, and apoptosis (90, 444, 600, 677) affects transvascular A 𝛃 clearance by promoting A 𝛃 42 efflux across the BBB (580).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [580]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“PSEN1 mutations lead to faster soluble-to-fibrillar conversion of A 𝛃 42 promoting amyloid deposition in the brain (303, 566, 580).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [580]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Autosomal-dominant AD (ADAD) is an inherited form of AD caused by mutations in amyloid precursor protein ( APP ) and presenilin-1 and 2 ( PSEN1; PSEN2 ) genes (49, 177, 303, 304, 580).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [580]
The cited source says what the claim attributes to it.
In the citing paper
“APOE4 is the major genetic risk factor for sporadic, late-onset AD (199, 368, 580, 612).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [580]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Finding the missing heritability of complex diseases
Manolio, T. A., Collins, F. S., Cox, N. J., Goldstein, D. B., Hindorff, L. A., Hunter, D. J., McCarthy, M. I., Ramos, E. M., Cardon, L. R., Chakravarti, A., et al. (2009) · Nature · doi:10.1038/nature08494 · Cited by 8,336
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659 · cited 3×
“Goate et al. (1991), then resequenced the same two APP exons to reveal the first EO-FAD mutation (London mutation; V717I) in APP.”
BackgroundThe precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor
Kang, J., Lemaire, H.-G., Unterbeck, A., Salbaum, J. M., Masters, C. L., Grzeschik, K.-H., Multhaup, G., Beyreuther, K., & Müller-Hill, B. (1987) · Nature · doi:10.1038/325733a0 · Cited by 4,619 · cited 1×
“In 1987, we as well as others isolated the amyloid b (A4) protein precursor (APP; Goldgaber et al. 1987; Kang et al. 1987; Tanzi et al. 1987a, 1988) and mapped it to chromosome 21.”
BackgroundCloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051 · cited 3×
“1987b); they were ultimately demonstrated to carry PSEN1 mutations (Sherrington et al. 1995).”
BackgroundSelf-citationHarold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326 · cited 14×
“Genetic association studies remain the most common method for identifying novel LOAD genes and are most often employed in the form of large-scale GWASs that screen the entire human genome for novel disease loci.”
InfluentialScheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-864 · Cited by 2,599 · cited 3×
“Whether EO-FAD mutations appear in APP near the g-secretase cleavage site or in the presenilins, the vast majority of them serve to increase the ratio of Ab42:Ab40. g-Secretase modulators are aimed at reversing this ratio and represent very promising compounds for treating and preventing AD based on what has been garn…”
BackgroundSelf-citationCandidate gene for the chromosome 1 familial Alzheimer’s disease locus
Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D. M., Oshima, J., Pettingell, W. H., Yu, C.-E., Jondro, P. D., Schmidt, S. D., Wang, K., et al. (1995) · Science · doi:10.1126/science.7638622 · Cited by 2,577 · cited 1×
“Shortly thereafter, we first reported a homolog of PSEN1 called presenilin (PSEN2; Levy-Lahad et al. 1995) on chromosome 1 and showed that it harbors the N141I mutation in Volga-German EO-FAD families.”
BackgroundSelf-citationGenome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease
the European Alzheimer's Disease Initiative Investigators, Lambert, J.-C., Heath, S., Even, G., Campion, D., Sleegers, K., Hiltunen, M., Combarros, O., Zelenika, D., Bullido, M. J., et al. (2009) · Nature Genetics · doi:10.1038/ng.439 · Cited by 2,234
Rogaev, E. I., Sherrington, R., Rogaeva, E. A., Levesque, G., Ikeda, M., Liang, Y., Chi, H., Lin, C., Holman, K., Tsuda, T., et al. (1995) · Nature · doi:10.1038/376775a0 · Cited by 2,052 · cited 1×
“This was confirmed by Rogaev et al. (1995) shortly afterward.”
Siglecs and their roles in the immune system
Crocker, P. R., Paulson, J. C., & Varki, A. (2007) · Nature Reviews Immunology · doi:10.1038/nri2056 · Cited by 2,031
Initiative, T. A. D. N., Hollingworth, P., CHARGE consortium, EADI1 consortium, Harold, D., Sims, R., Gerrish, A., Lambert, J.-C., Carrasquillo, M. M., Abraham, R., et al. (2011) · Nature Genetics · doi:10.1038/ng.803 · Cited by 1,997 · cited 5×
“1 10% Clearance of Ab; innate immunity CR1 Complement component (3b/4b) receptor 1 1q32 15% Clearance of Ab; innate immunity PICALM Phosphatidylinositol binding clathrin assembly molecule 11q14 15% Production and clearance of Ab; cellular signaling BIN1 Bridging integrator 1 2q14 15% Production and clearance of Ab; ce…”
BackgroundInfluentialProtective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease
Corder, E. H., Saunders, A. M., Risch, N. J., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Rimmler, J. B., Locke, P. A., Conneally, P. M., Schmader, K. E., et al. (1994) · Nature Genetics · doi:10.1038/ng0694-180 · Cited by 1,920 · cited 2×
“In contrast, the 12 allele of APOE exerts “protective” effects (Corder et al. 1994).”
BackgroundWolfe, M. S., Xia, W., Ostaszewski, B. L., Diehl, T. S., Kimberly, W. T., & Selkoe, D. J. (1999) · Nature · doi:10.1038/19077 · Cited by 1,916
Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database
Bertram, L., McQueen, M. B., Mullin, K., Blacker, D., & Tanzi, R. E. (2007) · Nature Genetics · doi:10.1038/ng1934 · Cited by 1,857
Self-citationTwenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective
Tanzi, R. E., & Bertram, L. (2005) · Cell · doi:10.1016/j.cell.2005.02.008 · Cited by 1,849
Self-citationDeficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein
De Strooper, B., Saftig, P., Craessaerts, K., Vanderstichele, H., Guhde, G., Annaert, W., Von Figura, K., & Van Leuven, F. (1998) · Nature · doi:10.1038/34910 · Cited by 1,818 · cited 2×
“Three years after their discovery in 1995, the presenilins were shown to be necessary for the generation of Ab from APP (De Strooper et al. 1998).”
BackgroundRole of Genes and Environments for Explaining Alzheimer Disease
Gatz, M., Reynolds, C. A., Fratiglioni, L., Johansson, B., Mortimer, J. A., Berg, S., Fiske, A., & Pedersen, N. L. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.2.168 · Cited by 1,798 · cited 1×
“However, it is estimated that up to 80% of AD involves the inheritance of genetic factors, based on twin and family studies (Gatz et al. 2006).”
BackgroundAlzheimer's disease and Down's syndrome: Sharing of a unique cerebrovascular amyloid fibril protein
Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(84)91209-9 · Cited by 1,693
Amyloid β Protein Gene: cDNA, mRNA Distribution, and Genetic Linkage Near the Alzheimer Locus
Tanzi, R. E., Gusella, J. F., Watkins, P. C., Bruns, G. A. P., St George-Hyslop, P., Van Keuren, M. L., Patterson, D., Pagan, S., Kurnit, D. M., & Neve, R. L. (1987) · Science · doi:10.1126/science.2949367 · Cited by 1,611
Self-citationMutation of the Alzheimer's Disease Amyloid Gene in Hereditary Cerebral Hemorrhage, Dutch Type
Levy, E., Carman, M. D., Fernandez-Madrid, I. J., Power, M. D., Lieberburg, I., van Duinen, S. G., Bots, G. T. A. M., Luyendijk, W., & Frangione, B. (1990) · Science · doi:10.1126/science.2111584 · Cited by 1,381
Goldgaber, D., Lerman, M. I., McBride, O. W., Saffiotti, U., & Gajdusek, D. C. (1987) · Science · doi:10.1126/science.3810169 · Cited by 1,333
Genome-wide Analysis of Genetic Loci Associated With Alzheimer Disease
Seshadri, S. (2010) · JAMA · doi:10.1001/jama.2010.574 · Cited by 1,219
The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease
Rogaeva, E., Meng, Y., Lee, J. H., Gu, Y., Kawarai, T., Zou, F., Katayama, T., Baldwin, C. T., Cheng, R., Hasegawa, H., et al. (2007) · Nature Genetics · doi:10.1038/ng1943 · Cited by 1,167 · cited 1×
“These include, for example, SORL1 (sortilin-related receptor), which is a sorting receptor that regulates the intracellular trafficking of a variety of proteins, including APP (Andersen et al. 2005; Rogaeva et al. 2007).”
BackgroundThe Genetic Defect Causing Familial Alzheimer's Disease Maps on Chromosome 21
St George-Hyslop, P. H., Tanzi, R. E., Polinsky, R. J., Haines, J. L., Nee, L., Watkins, P. C., Myers, R. H., Feldman, R. G., Pollen, D., Drachman, D., et al. (1987) · Science · doi:10.1126/science.2880399 · Cited by 1,163
Self-citationTanzi, R. E., McClatchey, A. I., Lamperti, E. D., Villa-Komaroff, L., Gusella, J. F., & Neve, R. L. (1988) · Nature · doi:10.1038/331528a0 · Cited by 1,096
Self-citationThe Alzheimer's Disease-Associated Amyloid β-Protein Is an Antimicrobial Peptide
Soscia, S. J., Kirby, J. E., Washicosky, K. J., Tucker, S. M., Ingelsson, M., Hyman, B., Burton, M. A., Goldstein, L. E., Duong, S., Tanzi, R. E., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009505 · Cited by 1,060 · cited 1×
“Interestingly, the innate immune system has recently gained increased attention in AD, with our discovery that Ab may act as an antimicrobial peptide in the brain’s innate immune system (Soscia et al. 2010).”
BackgroundSelf-citationThe Genetics of Alzheimer Disease: Back to the Future
Bertram, L., Lill, C. M., & Tanzi, R. E. (2010) · Neuron · doi:10.1016/j.neuron.2010.10.013 · Cited by 834
Self-citationWhole-Genome Sequencing in a Patient with Charcot–Marie–Tooth Neuropathy
Lupski, J. R., Reid, J. G., Gonzaga-Jauregui, C., Rio Deiros, D., Chen, D. C. Y., Nazareth, L., Bainbridge, M., Dinh, H., Jing, C., Wheeler, D. A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908094 · Cited by 759
The genetic epidemiology of neurodegenerative disease
Bertram, L. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24761 · Cited by 680
Andersen, O. M., Reiche, J., Schmidt, V., Gotthardt, M., Spoelgen, R., Behlke, J., von Arnim, C. A. F., Breiderhoff, T., Jansen, P., Wu, X., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503689102 · Cited by 655
Bertram, L., Lange, C., Mullin, K., Parkinson, M., Hsiao, M., Hogan, M. F., Schjeide, B. M. M., Hooli, B., DiVito, J., Ionita, I., et al. (2008) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2008.10.008 · Cited by 511 · cited 2×
“Whereas we had previously reported a CD33 SNP that increased risk for AD with genome-wide significant association (Bertram et al. 2008) using family-based GWASs, these two case–control GWASs reported an SNP roughly 1400 base pairs away that conferred protection against AD.”
BackgroundMethodSelf-citationA TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer's disease
Roses, A. D., Lutz, M. W., Amrine-Madsen, H., Saunders, A. M., Crenshaw, D. G., Sundseth, S. S., Huentelman, M. J., Welsh-Bohmer, K. A., & Reiman, E. M. (2010) · The Pharmacogenomics Journal · doi:10.1038/tpj.2009.69 · Cited by 391
Hu, J., Igarashi, A., Kamata, M., & Nakagawa, H. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m104068200 · Cited by 360
Hemming, M. L., & Selkoe, D. J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m508460200 · Cited by 332
Tebar, F., Bohlander, S. K., & Sorkin, A. (1999) · Molecular Biology of the Cell · doi:10.1091/mbc.10.8.2687 · Cited by 320
Kim, J., Castellano, J. M., Jiang, H., Basak, J. M., Parsadanian, M., Pham, V., Mason, S. M., Paul, S. M., & Holtzman, D. M. (2009) · Neuron · doi:10.1016/j.neuron.2009.11.013 · Cited by 308 · cited 4×
“Thus, the two LOAD-associated mutations in ADAM10 would appear to be strong candidates for the first rare, highly penetrant pathogenic mutations to be genetically associated with late-onset AD (Kim et al. 2009).”
BackgroundInfluentialTanzi, R. E., George-Hyslop, P. H. S., Haines, J. L., Polinsky, R. J., Nee, L., Foncin, J.-F., Neve, R. L., McClatchey, A. I., Conneally, P. M., & Gusella, J. F. (1987) · Nature · doi:10.1038/329156a0 · Cited by 269
Self-citationClusterin: A forgotten player in Alzheimer's disease
Nuutinen, T., Suuronen, T., Kauppinen, A., & Salminen, A. (2009) · Brain Research Reviews · doi:10.1016/j.brainresrev.2009.05.007 · Cited by 267
Variation in DCP1, encoding ACE, is associated with susceptibility to Alzheimer disease
Kehoe, P. G., Russ, C., McIlroy, S., Williams, H., Holmans, P., Holmes, C., Liolitsa, D., Vahidassr, D., Powell, J., McGleenon, B., et al. (1999) · Nature Genetics · doi:10.1038/5009 · Cited by 260 · cited 2×
“ACE is also able to degrade Ab in vitro (Hu et al. 2001; Hemming et al. 2005).”
BackgroundGenome-wide association studies in Alzheimer’s disease
Bertram, L., & Tanzi, R. E. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp406 · Cited by 257
Self-citationKounnas, M. Z., Danks, A. M., Cheng, S., Tyree, C., Ackerman, E., Zhang, X., Ahn, K., Nguyen, P., Comer, D., Mao, L., et al. (2010) · Neuron · doi:10.1016/j.neuron.2010.08.018 · Cited by 252
Self-citationAMPH-1/Amphiphysin/Bin1 functions with RME-1/Ehd1 in endocytic recycling
Pant, S., Sharma, M., Patel, K., Caplan, S., Carr, C. M., & Grant, B. D. (2009) · Nature Cell Biology · doi:10.1038/ncb1986 · Cited by 218
Complement Receptor 1: Disease associations and therapeutic implications
Khera, R., & Das, N. (2009) · Molecular Immunology · doi:10.1016/j.molimm.2008.09.026 · Cited by 213
The precursor of Alzheimer??s disease amyloid A4 protein resembles a cell-surface receptor
Kang, J., Lemaire, H.-G., Unterbeck, A., Salbaum, J., Masters, C., Grzeschik, K.-H., Multhaup, G., Beyreuther, K., & M??ller-Hill, B. (1987) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-198701030-00032 · Cited by 195
Peripheral clearance of amyloid β peptide by complement C3-dependent adherence to erythrocytes
Rogers, J., Li, R., Mastroeni, D., Grover, A., Leonard, B., Ahern, G., Cao, P., Kolody, H., Vedders, L., Kolb, W. P., et al. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.09.043 · Cited by 175 · cited 2×
“CR1 is the receptor for complement C3b, a key inflammatory molecule that is activated as part of the brain’s innate immune system in AD (Khera et al. 2009), and may be able to protect against Ab-induced neurotoxicity (Rogers et al. 2006).”
BackgroundNizzari, M., Venezia, V., Repetto, E., Caorsi, V., Magrassi, R., Gagliani, M. C., Carlo, P., Florio, T., Schettini, G., Tacchetti, C., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m610146200 · Cited by 93
Rademakers, R., Dermaut, B., Peeters, K., Cruts, M., Heutink, P., Goate, A., & Van Broeckhoven, C. (2003) · Human Mutation · doi:10.1002/humu.10269 · Cited by 75
Meta-analysis of linkage studies for Alzheimer's disease—A web resource
Butler, A. W., Ng, M., Hamshere, M. L., Forabosco, P., Wroe, R., Al‐Chalabi, A., Lewis, C. M., & Powell, J. F. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.03.013 · Cited by 68
Mines, M. A., Ding, Y., & Fan, G.-H. (2007) · Current Medicinal Chemistry · doi:10.2174/092986707782023686 · Cited by 57
Rademakers, R., Cruts, M., Sleegers, K., Dermaut, B., Theuns, J., Aulchenko, Y. S., Weckx, S., Pooter, T. D., den Broeck, M. V., Corsmit, E., et al. (2005) · The American Journal of Human Genetics · doi:10.1086/491749 · Cited by 54
The Tau R406W Mutation Causes Progressive Presenile Dementia with Bitemporal Atrophy
Ostojic, J., Elfgren, C., Passant, U., Nilsson, K., Gustafson, L., Lannfelt, L., & Froelich Fabre, S. (2004) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000077158 · Cited by 48
PEN–2 gene mutation in a familial Alzheimer’s disease case
Frigerio, C. S., Piscopo, P., Calabrese, E., Crestini, A., Campeggi, L. M., di Fava, R. C., Fogliarino, S., Albani, D., Marcon, G., Cherchi, R., et al. (2005) · Journal of Neurology · doi:10.1007/s00415-005-0799-7 · Cited by 34
Tanzi, R. E., McClatchey, A. I., Lamperti, E. D., Villa‐Komaroff, L., Gusella, J. F., & Neve, R. L. (1988) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-198802040-00013 · Cited by 8
Self-citation
Research works printed but not linked: 2
- Reiman EM, Webster JA, Myers AJ, Hardy J, Dunckley T, Zis- mann VL, Joshipura KD, Pearson JV, Hu-Lince D, Huen- telman MJ, et al. 2007. Papassotiropoulos A, Stephan DA. GAB2 alleles modify Alzheimer's risk in APOE 14 car- riers. Neuron 54: 713 -720.
- Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD. 1993. Apolipopro- tein E: High-avidity binding to b-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci 90: 1977-1981.
Cited by
Super-enhancers in the control of cell identity and disease
Hnisz, D., Abraham, B. J., Lee, T. I., Lau, A., Saint-André, V., Sigova, A. A., Hoke, H. A., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.09.053 · Cited by 3,662
Microglia Function in the Central Nervous System During Health and Neurodegeneration
Colonna, M., & Butovsky, O. (2017) · Annual Review of Immunology · doi:10.1146/annurev-immunol-051116-052358 · Cited by 2,894
Blood-Brain Barrier: From Physiology to Disease and Back
Sweeney, M. D., Zhao, Z., Montagne, A., Nelson, A. R., & Zlokovic, B. V. (2019) · Physiological Reviews · doi:10.1152/physrev.00050.2017 · Cited by 2,312
The Amyloid-β Pathway in Alzheimer’s Disease
Hampel, H., Hardy, J., Blennow, K., Chen, C., Perry, G., Kim, S. H., Villemagne, V. L., Aisen, P., Vendruscolo, M., Iwatsubo, T., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01249-0 · Cited by 1,952
“Over 200 mutations involving this complex have been observed [34].”
BackgroundHallmarks of neurodegenerative diseases
Wilson, D. M., Cookson, M. R., Van Den Bosch, L., Zetterberg, H., Holtzman, D. M., & Dewachter, I. (2023) · Cell · doi:10.1016/j.cell.2022.12.032 · Cited by 1,789
“3,9 A close relationship between lipid metabolism and microglial activation is emerging as lipid related genes are upregulated in the transition from homeostatic to damage-associated microglia.”
Metadata
- Authors
- Tanzi, R. E.
- Affiliations
- Harvard University (US)
- Corresponding author
- Tanzi, R. E.
- ORCID
- Tanzi, R. E.
- Venue
- Cold Spring Harbor Perspectives in Medicine
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2012-07-25
- Volume
- 2
- Issue
- 10
- Pages
- a006296-a006296
- ISSN
- 2157-1422 (ISSN-L)
- OpenAlex
- W4233829850
- Cited by
- 727
- References
- 55
- Citations by year
- 2026: 40 · 2025: 55 · 2024: 58 · 2023: 70 · 2022: 54 · 2021: 49 · 2020: 54 · 2019: 40 · 2018: 42 · 2017: 55 · 2016: 60 · 2015: 52 · 2014: 61 · 2013: 32 · 2012: 5
- Type
- posted content
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cold Spring Harbor Perspectives in Medicine (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- Alzheimer's disease, genetic susceptibility, familial Alzheimer's disease, APP mutations, presenilin 1, presenilin 2, apolipoprotein E, APOE ε4, late-onset Alzheimer's disease, twin and family studies, genome-wide association study, candidate genes, heritability
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.